Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.02 is 62% below its 2-year average of 0.04, near the low end of its 2-year range (-0.04–0.36).
As of the fiscal period ended Tuesday, June 30, 2026. 537.32% above its 12-month average of 0.00.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.02.
DEBT TO EQUITY RATIO
0.02
DEBT TO EQUITY RATIO AVG TTM
0.00
DEBT TO EQUITY RATIO AVG 3Y
N/A
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+537.32%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 774 covered companies
CURRENT VS SECTOR MEDIAN
-85.73%
vs the sector median at left
LB Pharmaceuticals Inc Common Stock
Market Cap
$979.22M
Debt to Equity Ratio
0.02
TTM Avg
0.00
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$978.24M
Debt to Equity Ratio
0.52
TTM Avg
0.95
3Y Avg
0.70
5Y Avg
0.50
Market Cap
$978.09M
Debt to Equity Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$971.74M
Debt to Equity Ratio
0.61
TTM Avg
0.74
3Y Avg
0.79
5Y Avg
0.93
Market Cap
$994.31M
Debt to Equity Ratio
N/A
TTM Avg
0.29
3Y Avg
0.20
5Y Avg
0.20
Market Cap
$995.51M
Debt to Equity Ratio
0.23
TTM Avg
0.21
3Y Avg
0.27
5Y Avg
0.36
Market Cap
$958.38M
Debt to Equity Ratio
0.02
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.00B
Debt to Equity Ratio
0.01
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.01
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LB Pharmaceuticals Inc Common Stock (LBRX) | $979.22M | 0.02 | 0.00 | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $978.24M | 0.52 | 0.95 | 0.70 | 0.50 |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $978.09M | N/A | N/A | N/A | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $971.74M | 0.61 | 0.74 | 0.79 | 0.93 |
| Vor Biopharma Inc. (VOR)vs › | $994.31M | N/A | 0.29 | 0.20 | 0.20 |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $995.51M | 0.23 | 0.21 | 0.27 | 0.36 |
| Aktis Oncology, Inc. (AKTS)vs › | $958.38M | 0.02 | N/A | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.00B | 0.01 | 0.01 | 0.01 | 0.01 |
| Immatics N.V. (IMTX)vs › | $1.01B | 0.04 | 0.03 | 0.05 | 0.11 |
| Savara Inc. (SVRA)vs › | $950.86M | 0.21 | 0.15 | 0.18 | 0.22 |
Debt/Equity
0.02
Current Ratio
15.08
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.02 |
| 2026-03-31 | 0.01 |
| 2025-12-31 | 0.01 |
| 2025-09-30 | 0.01 |
| 2025-06-30 | -0.04 |
| 2025-03-31 | 0.36 |
| 2024-09-30 | 0.00 |
| 2024-06-30 | 0.00 |
| 2024-03-31 | 0.00 |
